Results 131 to 140 of about 595,200 (266)

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

FUNCTIONAL CONDITION OF THE MYOCARDIUM IN ACUTE CORONARY SYNDROME

Российский кардиологический журнал, 2001
The study included 127 patients with various courses of angina and was targeted at the evaluation of myocardial functional condition with the usage of Doppler echo and Holter monitoring.
A. N. Zakirova, R. G. Oganov, N. E. Zakirova   +2 more
doaj  

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Cardiovascular outcome and home blood pressure in relation to silent myocardial ischemia in a clinical population: The J-HOP study. [PDF]

J Clin Hypertens (Greenwich), 2020
Shimizu H, Hoshide S, Kanegae H, Kario K.   +3 more
europepmc   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Diagnóstico de isquemia miocárdica silente en diabéticos tipo 2 mediante electrocardiograma, ergometría y Gated-SPECT Diagnosis of silent myocardial ischemia in type 2 diabetic patietns by electrocardiogram, ergometry and Gated-SPECT

Revista Cubana de Investigaciones Biomédicas, 2008
Para determinar la relación entre los factores de riesgos ateroscleróticos y la isquémica miocárdica silente fueron estudiados 31 pacientes diabéticos tipo 2 asintomáticos con exámenes de laboratorio, electrocardiograma, ergometría, Gated-SPECT y ...
Yamilé Peña Quián, José Fernández-Britto Rodríguez, Jorge Bacallao Gallestey, Juan Felipe Batista Cuéllar, Marco Antonio Coca Pérez, Noresma Toirac García, Andria Peña Coego   +6 more
doaj  

Microalbuminuria (Moderate Albumin Excretion) and its relationship with Silent myocardial ischemia in treatment naïve type II diabetic patients. [PDF]

Pak J Med Sci, 2020
Hussain Q, Bukhari MH, Afzaal F, Fatima W.   +3 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Clinical effectiveness of long-term trimetazidine MB therapy in patients with cardio-respiratory disease (the results of an open, prospective multi-centre study)

Кардиоваскулярная терапия и профилактика, 2009
Aim. To study the prevalence and clinical features of cardio-respiratory disease (CRD): coronary heart disease (CHD) + chronic obstructive pulmonary disease (COPD). To assess the long-term effectiveness of a myocardial cytoprotector, trimetazidine MB, as
N. M. Kolomoets, V. I. Baksheev, E. G. Zarubina, K. U. Uvaysova, A. V. Pleshakov   +4 more
doaj